Global expansion Jubilant Biosys is actively expanding its footprint with new offices and facilities in India and Southern Asia, and has recent activity in France through an 80% equity investment. This indicates readiness for cross-region collaboration and potential co-development or multinational CRO partnerships.

CRDMO leadership Positioned as a leading contract research, development and manufacturing organization with end-to-end capabilities including biologics, ADCs, mAbs, oligos, and peptides, Jubilant Biosys offers integrated discovery through GMP manufacturing—a strong fit for pharma companies seeking single-vendor efficiency and accelerated timelines.

Tech enablement Utilizes a mix of modern tech stack and digital tools (WordPress, Hyperion, PWA, analytics) alongside a focus on environment-friendly processes, signaling a readiness to adopt innovative, scalable workflows and potential for digital CRO programs or tech-enabled collaborations.

Strategic partnerships Past and ongoing collaborations with major pharma players (including Sanofi) and strong ESG and supply chain commitments present opportunities for expanded alliance models, co-development deals, and long-term contracted programs in CNS and other therapeutic areas.

Growth potential Revenue tier ($50M-$100M) and multi-site operations with 2,400+ employees indicate significant capacity to take on larger clinical and commercial manufacturing programs, opening sales opportunities for increased CDMO capacity, scale-up, and global supply enablement.